ğŸ›¡ï¸ OncoAudit: International Healthcare Audit Terminal (v2.0.0)
Closing the "Memory Hole" of administrative silence in global oncology healthcare.

ğŸ¥ Mission
This project leverages the AO Network and Arweave to provide a permanent, decentralized audit layer for cancer drug reimbursement and regulatory data. Our goal is to ensure that life-saving transparency is never erased by bureaucracy.

ğŸ“Š Global Audit Dashboard (v2.0.0 Global Expansion)
Current status of international regulatory administrative lag.

Target Drug,Case ID,Baseline (US FDA),Comparison Region,Status,Audit Delay
Rituxan,RIT-2026-JP,Oct 2012,Japan (MHLW),Deliberating,~13.2 Years
Xeljanz,XEL-2017-EU,Nov 2012,European Union,Safety Update,52 Months
Xeljanz,XEL-2013-TW,Nov 2012,Taiwan (TFDA),Approved,13 Months

ğŸš¨ Audit Discovery: Rituxan's 100mg/500mg dosage standards were settled by the FDA in 2012. However, our 2026 audit found the MHLW still deliberating partial changes for these same dosages in Japan, exposing a 13.2-year regulatory gap.

## ğŸ“Š The "7.6x Efficiency Gap" (The Core Audit)
This project uses the **AO Truth Machine** to benchmark the massive disparity in drug approval speeds between jurisdictions.

### ğŸš¨ Extreme Audit Discovery: 2,875 Days of Silence
Our system identified that **Tecentriq** faced an administrative silence of **2,875 Days (~8 Years)** in Taiwan. This is the ultimate "Memory Hole" we are sealing with AO.

| Drug Name | ğŸ‡¯ğŸ‡µ Japan (MHLW) | ğŸ‡¹ğŸ‡¼ Taiwan (NHIA) | The "Silence" Gap |
| :--- | :--- | :--- | :--- |
| **Tagrisso** | 58 Days | 1,225 Days | **21x Slower** |
| **Enhertu** | 60 Days | 458 Days | **7.6x Slower** |
| **Tecentriq** | Standardized | **2,875 Days** | **~8 Years of Silence** |

---

## ğŸ” Data Integrity & Evidence Verification

To ensure maximum transparency, **OncoAudit** benchmarks its findings against official regulatory sources:

* **Verified Taiwan Records:** All data points for **Tecentriq (2,875 days)** and **Tagrisso (1,225 days)** are cross-referenced with the official [Taiwan Cancer Drug Fund Platform (TmCDF)](https://tmcdfplatform.org.tw/).
* **The "Link Rot" Problem (Japan):** Our Japanese benchmark data (MHLW) recently encountered a **404 error** on the legacy web. This highlights the core value of OncoAudit: **We capture and seal these records on Arweave before they are erased or moved by government authorities.**
* **Global Strategy (v4.0):** In regions where digital data is unavailable or suppressed, OncoAudit provides a **"Truth Shelter"**â€”allowing NGOs and citizens to upload scans of physical documents directly to the AO network as immutable evidence.

---

## ğŸ› ï¸ Technical Architecture & Roadmap (v3.0)
We are evolving into a fully **Autonomous Monitoring Engine**.

### **Current Tech Stack:**
* **AO Network**: Parallel compute for multi-source fund flow verification.
* **Arweave**: Cryptographically sealing reports to prevent "Memory Holes".
* **AOS (Lua)**: Handling complex pharmaceutical data schemas.

### **Next Steps (The Pathfinder Path):**
* **[v3.0 Target] AO Cron Jobs:** Implementing 24/7 autonomous polling of regulatory APIs.
* **[Resource Allocation] AOS Scaling:** Utilizing the **$10,000 development grant** to recruit specialized **AOS (Lua) engineers** to build the multi-jurisdiction data normalization engine.
* **[Infrastructure] Compute Credits:** Leveraging the **$5,000 compute credits** to run high-frequency audit agents on AO.

---

## ğŸ“… Roadmap
- [x] **v1.0.0**: Local pilot for Taiwan drug fund tracking.
- [x] **v2.0.0**: International benchmarking (Japan) and AOS process migration.
- [ ] **v3.0**: **(Current Goal)** Automated ingestion via **AO Cron Jobs** & Multi-country expansion.
- [ ] **v4.0**: **Full-scale high-value drug coverage** and DAO-powered global healthcare justice protocol.

---
*Built with passion by a builder who believes that data can save lives.*
